UCB Biopharma SPRL operates as a pharmaceutical company. The Company manufactures and supplies wide range of medicines and drugs for neurology and immunology. UCB Biopharma serves customers worldwide.
In India, the Pharmaceutical business of UCB Biopharma SPRL is focused on biological products, anti-FcRn antibodies, tetrahydroisoquinoline derivatives, protein manufacture, bispecific format suitable for use in high-through-put screening, heteroaryl amides as inhibitors of protein aggregation.
UCB Biopharma SPRL filed patent application numbered 10079/DELNP/2014 that is titled TNF ALPHA MODULATING BENZIMIDAZOLES. This Patent Application has been granted as as Patent number 317421.
The invention covers pharmaceuticals compound. This invention covers a series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act that the Claims 1-15 of the present application attracts the provision of section 3(d) of the Patents Act as the claims concern to the mere new form of known substances already disclosed by the prior art documents. Furthermore, the claimed compounds could not show any significant enhancement with regards to therapeutic efficacy.
As a response to the said objection, the applicant submitted that there is no known substance at the priority date of the instant application. The compounds of the present invention are structurally different from the compounds disclosed.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
